Compare · A vs QTRX
A vs QTRX
Side-by-side comparison of Agilent Technologies Inc. (A) and Quanterix Corporation (QTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and QTRX operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $49.49B, about 340.9x QTRX ($145.2M).
- Over the past year, A is up 21.8% and QTRX is down 50.9% - A leads by 72.8 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- A has more recent analyst coverage (25 ratings vs 13 for QTRX).
- Company
- Agilent Technologies Inc.
- Quanterix Corporation
- Price
- $172.97-1.42%
- $2.87-6.37%
- Market cap
- $49.49B
- $145.2M
- 1M return
- +10.66%
- -7.73%
- 1Y return
- +21.82%
- -50.94%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2017
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 13
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest A
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
- SEC Form EFFECT filed by Agilent Technologies Inc.
- SEC Form 424B3 filed by Agilent Technologies Inc.
- Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
- CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent to Participate in J.P. Morgan U.S. All Stars Conference
- Director Boehnlein Glenn S was granted 817 shares (SEC Form 4)
Latest QTRX
- SEC Form 4 filed by Quanterix Corporation
- Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
- Director Magovcevic-Liebisch Ivana converted options into 4,224 shares, increasing direct ownership by 36% to 15,883 units (SEC Form 4)
- Director Mendel Scott was granted 4,398 shares, increasing direct ownership by 18% to 28,454 units (SEC Form 4)
- Director Donnelly William P was granted 6,964 shares, increasing direct ownership by 4% to 169,365 units (SEC Form 4)
- Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
- SEC Form 4 filed by Chief Commercial Officer Gute James Edward Jr.
- Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 38,452 units (SEC Form 4)
- Quanterix Names Dr. Yuri Fesko Chief Medical Officer